AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves.
about
Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Management of anticoagulant therapy for patients with prosthetic heart valves or atrial fibrillationEmbolic and bleeding events after modified Bentall procedure in selected patientsBlood flow velocity effects and role of activation delay time on growth and form of platelet thrombi.Antithrombotic therapy for prosthetic valves: routine treatment and special considerations.Asymptomatic large left-atrial ball thrombus. Secondary to mitral stenosis.The effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical mitral valve replacement.Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications.Perioperative anticoagulation in patients with mechanical heart valves undergoing elective surgery: results of a survey conducted among Korean physicians.Implications of using different methods to characterise anticoagulant control in patients with second generation mechanical heart valve prostheses.Use of oral anticoagulants in older patients.Interface between valve disease and ischaemic heart diseaseAntithrombotic therapy for valve disease: native and prosthetic valves.Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery.Oral anticoagulation and risk of death: a medical record linkage study.Antithrombotic therapy in cardiac embolism.Choice of heart valve prosthesis.Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60.Antithrombotic medication for cardioembolic stroke preventionTwenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprosthesesAntithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Drug insight: an overview of current anticoagulation therapy after heart valve replacement.Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk?Challenges in managing anticoagulant therapy in patients with heart valve prostheses.Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician.Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study.The effects of 21 and 23 milimeter aortic valve prosthesis on hemodynamic performance and functional capacity in young adultsAnticoagulation for mechanical heart valves in patients with and without atrial fibrillation.Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy.Prosthetic valve selection for middle-aged patients with aortic stenosis.Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves.Role of novel anticoagulants for patients with mechanical heart valves.The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties.Early postoperative bridging anticoagulation after mechanical heart valve replacement: a systematic review and meta-analysis.Implant surgery and oral anticoagulant therapy: case report.Which heart valve prosthesis for patients aged between 60 and 70 years?Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients.Optimal Intensity of Warfarin Therapy in Patients With Mechanical Aortic Valves.Low target-INR anticoagulation is safe in selected aortic valve patients with the Medtronic Open Pivot mechanical prosthesis: long-term results of a propensity-matched comparison with standard anticoagulation.
P2860
Q24187077-11DDB5FD-0727-490C-B05D-9A2776BF4083Q27341873-665E5522-24D4-495D-A148-CCB9842D6427Q28167261-33E49DB8-0932-4FB7-89CA-3F38AECAD415Q28219587-6483049B-263C-477C-AEB9-865FEA99390FQ30479354-20BC9E1D-BE81-4D4C-9532-C492466C93C4Q31805137-9C9D2382-EFB6-49A9-AB37-27784582ECAFQ33175490-46128900-1F92-47D9-871B-CDABDCB2C5AEQ33603765-0ED9D3DE-F12A-4290-BDB4-FC3EDE376714Q33651497-FE191F7C-55E5-45D7-8904-50BE970D0A0AQ33659307-AC183199-DE91-4E79-9D21-7B0DA1DACE82Q33837185-2A7192B2-6463-41B8-AA43-416959AFC7D4Q34000901-5E31DAF1-BDC0-4167-8958-EE138B69FDC9Q34012648-3292A398-A01E-40E1-9DC2-4869CD02FE83Q34027396-A7530CD3-4F8C-4BCE-9FE5-705E5270CA2EQ34065069-7BF83BB2-3DAF-4FD1-A464-A0FFFADB5FECQ34210279-50B2B517-009F-4F80-9AEC-7BB9FE0659DCQ34362901-73798670-7000-4F3F-BDBA-709E2A750B0CQ34637636-C18F9C31-9A22-475A-B018-DAD0C4A1E71AQ35044615-2C7E5B8A-D6EB-420D-B9AF-11FD30F7493BQ35142419-CEC2EB27-467C-4D94-AA73-4A4B5AA646E3Q35581325-F28DF031-7BAA-45A7-9B09-20AD31340E38Q35752576-0D512638-8BBA-4773-89FA-C14F34492EDFQ36239522-C4AEA1DC-9A8D-4692-90BC-FC66BF73FC10Q36703689-F38C6AC5-69EB-4F0D-BFAD-F1FA900848C3Q36815991-7CC32604-558F-4CD9-9927-1F94F149153EQ36975515-81305CF1-C3BB-4172-8A8F-27C61B2AF6D4Q37463870-B19EE64D-A097-4C00-BE48-9E72CEDCC9F5Q37722026-881C4745-1805-48E4-A04B-21CF84FC9156Q37738233-25788E4E-602D-413B-9BF1-2E5D67AC9B00Q37781101-30DCB709-B21C-4347-959A-504A36D2B39CQ37806608-CA67C342-67C3-434C-B746-EAE1E0FA1643Q37990454-0B975D79-966F-41D9-B9C4-162142026C02Q38244764-4A9C160D-F3AA-476F-81F4-506C8F206E6FQ38247892-75A9C7ED-5119-4EAB-990B-01926D01C570Q38547884-E34912D5-F25F-4B85-9670-ED206B88DC3BQ42169513-1FF43E87-A510-4091-A342-7DEA11BE656FQ43014845-070E78AB-402D-4CB3-B1A9-770EE3EE67B6Q44132363-B16CBBD2-BA8B-4325-B32E-4E7A31F9C5D7Q47856582-93A8ADEC-0894-405D-8C31-763E2777C11AQ48679193-D59B0EE9-519C-4512-A829-1C4E6C765F6D
P2860
AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
AREVA: multicenter randomized ...... nical prosthetic heart valves.
@en
AREVA: multicenter randomized ...... nical prosthetic heart valves.
@nl
type
label
AREVA: multicenter randomized ...... nical prosthetic heart valves.
@en
AREVA: multicenter randomized ...... nical prosthetic heart valves.
@nl
prefLabel
AREVA: multicenter randomized ...... nical prosthetic heart valves.
@en
AREVA: multicenter randomized ...... nical prosthetic heart valves.
@nl
P2093
P356
P1433
P1476
AREVA: multicenter randomized ...... nical prosthetic heart valves.
@en
P2093
Boissel JP
P304
P356
10.1161/01.CIR.94.9.2107
P407
P577
1996-11-01T00:00:00Z